3SOF

Back above the 50-day MA
Could be ready to rumble again....

Update to this thread......


Technicals
Last Price Quote is:
26.52%above 13-day EMA
15.65%above 50-day EMA

52wk Range: 0.01 - 0.27

Volume: 155,600
Avg Vol (3m): 59,280

Well let's keep an eye on her and see if she is ready to break this downtrend line.
Indicators have turned North, Back above the 13-MA
Give me some volume that will convince me !

VIA Pharmaceuticals (VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will soon initiate a third Phase II clinical trial for VIA-2291, its lead compound. VIA-2291 targets inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The new trial design utilizes Positron Emission Tomography with fluorodeoxyglucose tracer (FDG-PET) to measure the impact of VIA-2291 on reducing vascular inflammation in treated patients.

52wk Range: 0.04 - 0.14
Volume: 665,580
Avg Vol (3m): 138,630

Technicals
Percentage Gainer

Below are the 6 month, 1 year, 2 year and 3 year charts.......

Looks like POSC will start another run into the the mid teens. Get in before it is too late

When they pop ...Take notice! 

Positron is in the sweet spot with its cardiac PET technology. PharmAssist, a small footprint 'vending machine' for injectable radioactive imaging, also looks like a winner. The company confirms that their entering into a strategic partnership with a major player in medical equipment, as yet unnamed. Rumors of a buyout are also buzzing. The future looks bright for this 27-year-old microcap.


Technicals
Percentage Gainer

Last Price Quote is:
above 13-day EMA
above 50-day EMA
RS Rating: N/A 

Fundamentals
Key Data:
Market Cap (M): $47.75 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: N/A

INDIANAPOLIS, May 06, 2010 (BUSINESS WIRE) -- Positron Corporation (POSC) (the "Company") a molecular imaging solutions company focused on Nuclear Cardiology, announced the highlights from the Company's presentation before NASDAQ on May 5, 2010.

The Management of Positron Corporation introduced the Company at the NASDAQ Marketsite. This forum is of great value to Positron since it provides broad exposure and access to a far reaching investment community.

The Company set out to explain the foundation of its business, the confirmation of a strategic partnership and potential revenue. Management discussed most all aspects of the Company's plans which it was at liberty to disclose. A transcript of the presentation will be filed with the Securities and Exchange Commission on a Form 8-K immediately when it becomes available in coming days.

Positron representatives did confirm an agreement with an industry leading strategic partner that will give the Company the ability to greatly expand the Company's revenue stream and our position in the molecular imaging market by offering imaging systems and radiopharmaceutical distribution. Patrick Rooney, Positron Corporation's CEO states, "We would have liked to introduce a certain synergistic business partner as was stated in the press; however it was the recommendation of both companies to not disclose further details due to a potential expansion relationship and certain strategic competitive advantages. We anticipate additional information will be disclosed in the near future."

Positron also gave guidance as to its target revenue. Based on the Company's research and unique positioning in the marketplace, Positron projects significant sales growth quarter over quarter, year over year. Positron projects that in the next 5 years the nuclear cardiology market will approach $1.5 Billion in revenue annually. The projections reflected sales from Positron's PET device and radiopharmaceutical devices and services. Positron may potentially achieve greater revenue as it expands into new markets with broader indications that we expect will be fully supported by Medicare and private payers.

About Positron: Positron founded in 1983, is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Positron products include: the Attrius(TM), a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the Tech-Assist(TM), a radiopharmaceutical injection shield. Positron is headquartered in Indianapolis, Indiana. More information about Positron is available at www.positron.com .

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

For further information please contact Positron Corporation at (317) 576-0183.

SOURCE: Positron Corporation


Positron Corporation
Patrick Rooney
(317) 576-0183